



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

#27

Charles Van Horn
Finnegan Henderson Farabow Garrett & Dunner, LLP
1300 I Street NW
Washington DC 20005-3315

Re: Patent Term Extension
Application for
U.S. Patent No. 4,668,669

MAILED


JAN 16 2004

REEXAM UNIT

Dear Mr. Van Horn:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,668,669 for a period of 1,333 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the PSC Forms Download Website:
<http://forms.psc.gov/forms/FDA/fda.html>.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.


Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: David T. Read
Health Assessment Policy Staff
Acting Director Health Assessment Policy Staff, CDER
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852

RE: SYNERCID®

FDA Docket No.: 00N-1251

UNITED STATES PATENT AND TRADEMARK OFFICE

(12)

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 4,668,669
(45) ISSUED : May 26, 1987
(75) INVENTOR : Jean-Claude Barriere, et al.
(73) PATENT OWNER : Aventis Pharma S.A.
(95) PRODUCT : SYNERCID® (quinupristin and dalfopristin)


This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,668,669 based upon the regulatory review of the product SYNERCID® (quinupristin and dalfopristin)(NDA 50-747) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 1,333 days

from January 10, 2006, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 7th day of January 2004.


JAMES E. ROGAN
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office